A respected RNAi therapeutics company.

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, today that it has offered new pre-clinical data with ALN-CC5 announced, an RNAi therapeutic targeting complement component C5. These data had been presented at the 6th International Meeting on Complement Therapeutics being held June 18 – 23, 2013 in Kos, Greece cialis generico . The complement program plays a central part in immunity as a protective mechanism for host defense, but its dysregulation results in serious, life-threatening complications in a broad selection of human diseases including paroxysmal nocturnal hemoglobinuria , atypical hemolytic-uremic syndrome , myasthenia gravis, neuromyelitis optica, and the like.

He plans to investigate if the mitochondria disposal procedure is relevant to this disease, the next leading reason behind blindness worldwide. However the implications of the results exceed the optic nerve mind, Marsh-Armstrong says, as a buildup of ‘garbage’ inside cells causes neurodegenerative illnesses such as Parkinson's, Alzheirmer's and ALS. ‘By showing that type of choice disposal happens, we've exposed the entranceway for others to investigate whether similar processes might be taking place with other cell types and cellular parts apart from mitochondria,’ he says..

Other entries from category "clinical":

Random entries